PDCD1LG2

programmed cell death 1 ligand 2

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PDCD1LG2 EXPRESSION1
Pembrolizumab	Malignant Head and Neck NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	3	submitted	EID5917 PD-L2 was detected in the absence of PD-L1 in some tumor types. Both PD-L1 and PD-L2 positivity significantly predicted clinical response to pembrolizumab on combined tumor, stromal and immune cells, … (full text at CIViC) PMID 28619999 · Yearley et al., 2017 · Open in CIViC	civic

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved7 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Skin Cutaneous Melanoma TCGA-SKCM	Cutaneous Melanoma	Ssm

Literature

Data not yet available

No publication linked to this gene yet.